Our study shows that its early changes, just 15 days after treatment begins, very clearly predict which patients are responding. It is a tool that can help us better understand treatment response and move toward increasingly personalized care in metastatic breast cancer," says Dr. Ángel Guerrero Zotano, one of the researchers involved in this study and member of GEICAM's Board of Directors.

Researchers are testing CAR T-cell therapy as a treatment for lupus, Graves’ disease and other conditions in which the body’s defenses go rogue

Prognostic Impact of Prostate-Specific Antigen at 6 Months After Radiotherapy in Localized Prostate Cancer: An Individual Patient Data Analysis of Randomized Trials National estimates of cancer clinical trial participation are nearly two decades old and ...

New drugs have made America’s deadliest cancer more treatable than ever. So why aren’t they reaching patients?

Olympus said Tuesday it has agreed to buy Israel-based BioProtect for $270 million to expand its product portfolio in oncology and urology.  BioProtect makes a balloon spacer system that separates the prostate from other structures during cancer radiation treatment.